Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

Q. Allergan ran a long-term study on silicone breast implants in 2009. I always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced that it had raised additional funding to scale and drive continued ...

NICE estimates that around 300,000 people could be eligible for treatment with Leqvio (inclisiran), and use of the drug will reduce the 10-year risk of a heart attack or death from 29% to 20%.